RT Journal Article
SR Electronic
T1 Oxygen saturation and acute mountain sickness during repeated altitude exposures simulating high-altitude working schedules
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.20.24319405
DO 10.1101/2024.12.20.24319405
A1 Waldner, N.
A1 Hartmann, S. E.
A1 Muralt, L.
A1 Lichtblau, M.
A1 Bader, P. R.
A1 Rawling, J. M.
A1 Lopez, I.
A1 Ulrich, S.
A1 Poulin, M. J.
A1 Bloch, K.E.
A1 Furian, M.
YR 2024
UL http://medrxiv.org/content/early/2024/12/24/2024.12.20.24319405.abstract
AB Objective To quantify the effect of two consecutive prolonged, intermittent exposures to high and very high altitudes on oxygen saturation (SpO2) and acute mountain sickness (AMS).Methods Healthy lowlanders (N=21), aged 18-30y, underwent two 7-day sojourns at the ALMA observatory, Chile (6hrs/day at 5050m, 18hrs/day at 2900m), separated by 1-week at 520m. SpO2 (pulse oximetry) and AMS severity (AMSc, Environmental Symptom Questionnaire cerebral score) diagnosing AMS (AMSc≥0.7) were assessed daily at both altitudes. www.ClinicalTrials.gov:NCT02730143.Results SpO2 at 2900m and 5050m on arrival day was mean±SD 93.6±0.5% and 79.9±1.0% (P<0.05 between altitudes), whereas the AMSc scores were 0.43±0.08 and 0.97±0.11 (P<0.05 between altitudes), respectively. At 2900m during a 7-day intermittent hypoxic exposure, SpO2 increased by a mean(95%CI) 0.3%/day(0.1;0.4) and by 0.9%/day(0.4;1.3) at 5050m. Similarly, AMSc decreased by 0.05points/day(0.01;0.08) at 2900m and by 0.16points/day(0.11;0.21) at 5050m. During the second sojourn (vs. 1 sojourn), day1, SpO2 at 2900m was unchanged but higher at 5050m by 2.9%(0.6;5.3). AMSc was lower at 2900m and 5050m by 0.37(0.16;0.59) and 0.37(0.11;0.63) (P<0.05 both comparisons vs 1 sojourn), respectively. Acclimatization with the 2 sojourn resulted in an increase in SpO2 at 2900m by 0.3%/day(0.1;0.4) and at 5050m: 0.5%/day(0.1;0.8). AMSc remained unchanged with acclimatization at 2900m but decreased at 5050m by 0.08points/day(0.04;0.11).Conclusions In healthy lowlanders, a 7-day intermittent hypobaric hypoxic exposure of varying severity at high and very high altitude improved SpO2 and AMS severity at 2900m, with larger improvements at 5050m. During a second identical sojourn, initial AMS severity was reduced despite comparable SpO2 at 2900m compared to the 1 sojourn. No further acclimatization effects were observed in SpO2 but in AMS symptoms at 2900m. In contrast, re-exposure to 5050m showed higher initial SpO2 and lower AMSc values with further improvement with intermittent re-exposures. These findings highlight altitude-dependent acclimatization patterns and confirm the effectiveness of pre-conditioning to prevent AMS when planning sojourns to high altitudes.Competing Interest StatementMF, KEB and SU are supported by the Swiss National Science Foundation. MJP is supported by a Discovery Grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada (Principal Investigator (PI), MJP; 2014-05554), and a CIHR Operating Grant on the Regulation of cerebral blood flow in OSA (PI: MJP). SH received support from the Dr Chen Fong doctoral scholar-ship (Hotchkiss Brain Institute).Clinical TrialNCT02731456Funding StatementMF, KEB and SU are supported by the Swiss National Science Foundation. MJP is supported by a Discovery Grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada (Principal Investigator (PI), MJP; 2014-05554), and a CIHR Operating Grant on the Regulation of cerebral blood flow in OSA (PI: MJP). SH received support from the Dr Chen Fong doctoral scholar-ship (Hotchkiss Brain Institute).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Conjoint Health Research Ethics Board of the University of Calgary (Ethics ID: REB 15-2709) and the Cantonal Ethics Committee of Zurich (2016-00048) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.